Journal Finder

* Biological Abstracts® (Thomson ISI) * BIOSIS Previews® (Thomson ISI) * Biotechnology & Bioengineering Abstracts (CSA/CIG) * Biowizard (Biowizard) * CAB Abstracts® (CABI) * Cambridge Scientific Abstracts (CSA/CIG) * Chemical Abstracts Service/SciFinder (ACS) * CSA Biological Sciences Database (CSA/CIG) * CSA Environmental Sciences & Pollution Management Database (CSA/CIG) * Current Awareness in Biological Sciences (Elsevier) * Current Contents®/Life Sciences (Thomson ISI) * EMBASE/Excerpta Medica (Elsevier) * Google Scholar * Index Copernicus (IC) * Index Medicus/MEDLINE/PubMed (NLM) * Journal Citation Reports/Science Edition (Thomson ISI) * PASCAL Database (INIST/CNRS) * Reference Update (Thomson ISI) * Science Citation Index Expanded™ (Thomson ISI) * Science Citation Index® (Thomson ISI) * SCOPUS (Elsevier) * Web of Science (Thomson ISI).

International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field.This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.The Red Journal's sister publication is Practical Radiation Oncology. Click here to see which types of papers these journals typically accept.

Manuscripts from key conferences dealing with cancer and closely related research fields, or a related group of papers on specific subjects of importance to cancer research, are considered for publication, with the understanding that they have not been published previously and are submitted exclusively to the Journal of the National Cancer Institute Monographs. All material submitted for consideration will be subject to review, when appropriate, by at least one outside reviewer and one member of the Editorial Board of the Journal of the National Cancer Institute. Opinions expressed by authors are not necessarily those of the publisher or the editors.

Japanese Journal of Clinical Oncology is a multidisciplinary journal for clinical oncologists which strives to publish high quality manuscripts addressing medical oncology, clinical trials, radiology, surgery, basic research, and palliative care. The journal aims to contribute to the world’s scientific community with special attention to the area of clinical oncology and the Asian region.JJCO publishes various articles types including:*Original Articles*Case Reports*Clinical Trial Notes*Cancer Genetics Reports*Epidemiology Notes*Technical Notes*Short Communications*Letters to the Editors*Solicited ReviewsThe journal also welcomes interim articles on the design and plan of phase studies before actual results are obtained. While clinical trials usually require a long time to accomplish a conclusive outcome, the journal believes reports of interim outcomes will be highly appreciated by its audience. .

Journal for ImmunoTherapy of Cancer is an open access, peer reviewed journal that encompasses all aspects of tumor immunology and cancer immunotherapy, from basic research through to clinical applications.The journal welcomes submissions in the following areas and other related topics:Basic Tumor ImmunologyTumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions with the anti-tumor immune responseClinical/Translational Cancer ImmunotherapyFirst-in-man clinical trials, phase II/III clinical studies, immune monitoring investigations, tumor microenvironment, host genetics and clinical outcomeImmunotherapy BiomarkersPredictive/prognostic biomarker studies, gene expression studies in cancer immunotherapy, serological immune biomarkers, multiparameter flow cytometry-defined immune biomarkers, high content immunohistological studiesReviews/EditorialsTriggering discussion on hot topics and innovative concepts

Journal for ImmunoTherapy of Cancer is the official journal of the Society for Immunotherapy of Cancer (SITC). The Society for Immunotherapy of Cancer (SITC) is a 501 (c)(3) non-profit society of medical professionals that was established in 1984 to exchange, encourage and promote information about the promise and breakthroughs of biological therapies, including immunotherapy, for patients with cancer. SITC is the world's leading member society of medical professionals dedicated to advancing cancer immunotherapy through its initiatives, educational sessions, and collaborative endeavors. The society has become THE forum for innovative discussions in the field.

The 'Journal of Cancer Research and Clinical Oncology' publishes significant and up-to-date articles within the fields of experimental and clinical oncology. The journal, which is chiefly devoted to Original papers and Rapid communications (given priority treatment by the Editors), also includes Reviews as well as Editorials and Guest editorials on current, controversial topics. The section Letters to the editors provides a forum for a rapid exchange of comments and information concerning previously published papers and topics of current interest. Meeting reports provide current information on the latest results presented at important congresses. The following fields are covered: carcinogenesis - etiology, mechanisms; molecular biology; recent developments in tumor therapy; general diagnosis; laboratory diagnosis; diagnostic and experimental pathology; oncologic surgery; and epidemiology.

JCO publishes original research, reviews and other material related to breast cancer, gastrointestinal cancer, hematologic malignancies, molecular oncology, lung cancer, genitourinary cancer, head and neck cancer, pediatric oncology, neurooncology, supportive care and quality of life issues, prevention, and phase I and clinical pharmacology. Its readership comprises practicing clinical oncologists, researchers, students, individuals in training, and allied health professionals throughout the world. Members of the American Society of Clinical Oncology as well as nonmember subscribers and patrons of medical libraries globally utilize the groundbreaking research published in each issue of JCO.

Publication office: Taylor & Francis, Inc., 325 Chestnut Street, Suite 800, Philadelphia, PA 19106.

The journal is devoted to the rapid publication of innovative preclinical investigations on therapeutic agents against cancer and pertinent findings of experimental and clinical oncology. In the journal you will find review articles, original articles, and short communications on all areas of cancer research, including but not limited to preclinical experimental therapeutics; anticancer drug development; cancer biochemistry; biotechnology; carcinogenesis; cancer cytogenetics; clinical oncology; cytokine biology; epidemiology; molecular biology; pathology; pharmacology; tumor cell biology; and experimental oncology. Papers concerning work on humans must comply with the principles of the declaration of Helsinki (1964). The approval of an ethical committee must then be stated on the manuscript. The editors reserve the right to reject a paper with questionable ethical justification.

Journal of Hematology & Oncology provides a forum for top-quality research in the fields of hematology and oncology.

The Journal of Immunotherapy publishes basic scientific and clinical studies of the immunologic response to tumors and other diseases. It addresses the latest advances in basic cytokine research (interferons, interleukins, and newly described factors); immune regulation; immune response to diseases and associated antigens; growth factors and their receptors; hematopoietic factors; monoclonal antibodies; therapeutic studies in animal models; immunotherapy research, including active immunization and adaptive immunotherapy in animal models and humans; and clinical trials. 160;.

Journal of Mammary Gland Biology and Neoplasia provides researchers within and outside the field of mammary gland biology with an integrated source of information derived from studies of the development, function, and pathology of the mammary gland. This quarterly journal offers comprehensive analyses of all aspects of the field, considering the fundamental biology and pathology of the mammary gland including, but not restricted to mammary development, the biology of breast cancer, lactation, milk proteins, bioactive agents in milk, hormonal regulation, growth factors, signal transduction, nutrition, and genetics. Each outstanding issue, guest edited by prominent authorities in the field, contains a series of minireviews encompassing a single topic. Researchers in the field of mammary gland biology, dairy scientists, and breast cancer researchers, as well as cell biologists, medical scientists, oncologists, nutritionists, pediatricians, and obstetricians will benefit from this quarterly.

The Journal of Neuro-Oncology is a multi-disciplinary journal encompassing basic, applied, and clinical investigations in all research areas as they relate to cancer and the central nervous system. It provides a single forum for communication among neurologists, neurosurgeons, radiotherapists, medical oncologists, neuropathologists, neurodiagnosticians, and laboratory-based oncologists conducting relevant research. The Journal of Neuro-Oncology does not seek to isolate the field, but rather to focus the efforts of many disciplines in one publication through a format which pulls together these diverse interests. More than any other field of oncology, cancer of the central nervous system requires multi-disciplinary approaches. To alleviate having to scan literally dozens of journals of cell biology, pathology, laboratory and clinical endeavours, JNO is a periodical in which current, high-quality, relevant research in all aspects of neuro-oncology may be found.

The aim of the Journal of Oral Pathology & Medicine is to publish manuscripts of high scientific quality representing original clinical, diagnostic or experimental work in oral pathology and oral medicine. Papers advancing the science or practice of these disciplines will be welcomed, especially those which bring new knowledge and observations from the application of techniques within the spheres of light and electron microscopy, tissue and organ culture, immunology, histochemistry and immunocytochemistry, microbiology, genetics and biochemistry. Review papers on topical and relevant subjects will receive a high priority. Original research material requiring rapid publication because of their significance and timeliness will be included as Brief Reports. They should not exceed three pages. All submitted manuscripts falling within the overall scope of the Journal will be assessed by at least two suitably qualified referees. Rapid publication.